As of May, 4 The EPS for Accelerate Diagnostics, Inc. (AXDX) Expected At $-0.31

April 16, 2018 - By Rebecca Betts

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Corporate Logo
Big Money Sentiment decreased to 0.81 in 2017 Q4. It has change of 0.82, from 2017Q3’s 1.63. The ratio worsened due to Accelerate Diagnostics, Inc. positioning: 21 sold and 32 reduced. 15 funds took holdings and 28 increased holdings. Investors holded 21.32 million in 2017Q3 but now own 19.90 million shares or 6.66% less.
Voya Invest Management Ltd Com, a Georgia-based fund reported 11,589 shs. Manufacturers Life Insur The stated it has 0% in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Schwab Charles Investment Mngmt, a California-based fund reported 128,814 shs. Barclays Public Ltd Co stated it has 0% in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Tci Wealth Advisors Inc owns 500 shs. Rhumbline Advisers has invested 0% in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Miura Glob Management Limited owns 300,000 shs or 2.28% of their US capital. State Board Of Administration Of Florida Retirement Sys invested in 0% or 16,068 shs. 61,023 were reported by Tiaa Cref. Northern, a Illinois-based fund reported 332,923 shs. Barbara Oil holds 0.15% in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) or 9,000 shs. New York-based Cannell Peter B Inc has invested 1.01% in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Swiss Bancorporation has 55,900 shs for 0% of their capital. Qs Invsts Ltd Liability Company owns 18 shs or 0% of their US capital. Vanguard Gp holds 0% or 1.33 million shs in its capital.

Accelerate Diagnostics, Inc. registered $1.50 million net activity with 5 insider buys and 0 selling transactions since October 17, 2017.

Earnings report for Accelerate Diagnostics, Inc. (NASDAQ:AXDX) is expected On May, 4., Zacks reports. Analysts forecast 14.81 % diference or $-0.31 from the $-0.27 EPS from 2017. Wall Street predicts 14.81 % negative EPS growth as of May, 4. The stock decreased 1.24% or $0.3 during the last trading session, reaching $23.9.Currently Accelerate Diagnostics, Inc. is downtrending after 0.88% change in last April 16, 2017. AXDX has also 85,758 shares volume. The stock underperformed the S&P500 by 12.43%.

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States.The company has $1.33 billion market cap. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.Last it reported negative earnings. The firm was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: